196 related articles for article (PubMed ID: 29281559)
1. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
Mato AR; Clasen S; Pickens P; Gashonia L; Rhodes J; Svoboda J; Hughes M; Nabhan C; Ali N; Schuster S; Carver J
Cancer Biol Ther; 2018 Jan; 19(1):1-2. PubMed ID: 29281559
[TBL] [Abstract][Full Text] [Related]
2. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Coutre SE; Byrd JC; Hillmen P; Barrientos JC; Barr PM; Devereux S; Robak T; Kipps TJ; Schuh A; Moreno C; Furman RR; Burger JA; O'Dwyer M; Ghia P; Valentino R; Chang S; Dean JP; James DF; O'Brien SM
Blood Adv; 2019 Jun; 3(12):1799-1807. PubMed ID: 31196847
[TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
[TBL] [Abstract][Full Text] [Related]
5. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
6. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.
Jiang L; Li L; Ruan Y; Zuo S; Wu X; Zhao Q; Xing Y; Zhao X; Xia S; Bai R; Du X; Liu N; Ma CS
Heart Rhythm; 2019 Sep; 16(9):1374-1382. PubMed ID: 30959203
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for the development of atrial fibrillation on ibrutinib treatment.
Lentz R; Feinglass J; Ma S; Akhter N
Leuk Lymphoma; 2019 Jun; 60(6):1447-1453. PubMed ID: 30730240
[TBL] [Abstract][Full Text] [Related]
9. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
Stephens DM; Byrd JC
Blood; 2019 Mar; 133(12):1298-1307. PubMed ID: 30642919
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger J; Borthakur G; Takahashi K; Estrov Z; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Sasaki K; Kanagal-Shamanna R; Patel K; Jorgensen J; Garg N; Wang X; Sondermann K; Cruz N; Wei C; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda W
N Engl J Med; 2019 May; 380(22):2095-2103. PubMed ID: 31141631
[TBL] [Abstract][Full Text] [Related]
11. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Xiao L; Salem JE; Clauss S; Hanley A; Bapat A; Hulsmans M; Iwamoto Y; Wojtkiewicz G; Cetinbas M; Schloss MJ; Tedeschi J; Lebrun-Vignes B; Lundby A; Sadreyev RI; Moslehi J; Nahrendorf M; Ellinor PT; Milan DJ
Circulation; 2020 Dec; 142(25):2443-2455. PubMed ID: 33092403
[TBL] [Abstract][Full Text] [Related]
13. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
[TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
Shanafelt TD; Parikh SA; Noseworthy PA; Goede V; Chaffee KG; Bahlo J; Call TG; Schwager SM; Ding W; Eichhorst B; Fischer K; Leis JF; Chanan-Khan AA; Hallek M; Slager SL; Kay NE
Leuk Lymphoma; 2017 Jul; 58(7):1630-1639. PubMed ID: 27885886
[TBL] [Abstract][Full Text] [Related]
15. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta P; Loscertales J; Terol MJ; Ramírez Payer Á; Ortiz M; Pérez I; Cuellar-García C; Fernández de la Mata M; Rodríguez A; Lario A; Delgado J; Godoy A; Arguiñano Pérez JM; Berruezo MJ; Oliveira A; Hernández-Rivas JÁ; García Malo MD; Medina Á; García Martin P; Osorio S; Baltasar P; Fernández-Zarzoso M; Marco F; Vidal Manceñido MJ; Smucler Simonovich A; López Rubio M; Jarque I; Suarez A; Fernández Álvarez R; Lancharro Anchel A; Ríos E; Losada Castillo MDC; Pérez Persona E; García Muñoz R; Ramos R; Yáñez L; Bello JL; Loriente C; Acha D; Villanueva M
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e985-e999. PubMed ID: 34511320
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
Stühlinger MC; Weltermann A; Staber P; Heintel D; Nösslinger T; Steurer M
Wien Klin Wochenschr; 2020 Feb; 132(3-4):97-109. PubMed ID: 31414181
[TBL] [Abstract][Full Text] [Related]
17. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
Thorp BC; Badoux X
Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
[TBL] [Abstract][Full Text] [Related]
18. Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
Zhou Y; Lu H; Yang M; Xu C
Medicine (Baltimore); 2019 Aug; 98(33):e16915. PubMed ID: 31415440
[TBL] [Abstract][Full Text] [Related]
19. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Gülsaran SK; Baysal M; Demirci U; Baş V; Kirkizlar HO; Umit E; Demir AM
J Oncol Pharm Pract; 2020 Mar; 26(2):478-480. PubMed ID: 31142233
[TBL] [Abstract][Full Text] [Related]
20. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Ahn IE; Farooqui MZH; Tian X; Valdez J; Sun C; Soto S; Lotter J; Housel S; Stetler-Stevenson M; Yuan CM; Maric I; Calvo KR; Nierman P; Hughes TE; Saba NS; Marti GE; Pittaluga S; Herman SEM; Niemann CU; Pedersen LB; Geisler CH; Childs R; Aue G; Wiestner A
Blood; 2018 May; 131(21):2357-2366. PubMed ID: 29483101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
